What to Do When Your Insurance Denies a Prescription

A denied prescription means your plan has decided not to pay, and that decision is reviewable through a process the plan is obliged to operate. There is normally an internal appeal, an independent external review after that, and a faster track when waiting would cause harm. A large share of first-level denials are overturned on a second look, usually because the original submission was missing a detail rather than because anyone changed their mind.

First, work out what kind of “no” you received

Different denials sit at different points, and only some of them are appeals. Sorting this out first saves the most time.

A rejection at the pharmacy counter is an automated billing response and often is not a denial at all. It may mean an eligibility mismatch, a quantity limit, or a missing authorisation. Many resolve in minutes. See what it means when a pharmacy says your claim was rejected.
A refused prior authorisation is a real coverage decision, made after clinical review, and it is appealable. See what prior authorization is and how the process actually works.
A step-therapy refusal means the plan wants a preferred drug tried first. The route is an exception request rather than an appeal. See what step therapy is and why you are told to try another drug first.
A formulary exclusion means the drug is not on the list at all. The route is a formulary exception request arguing the covered alternatives are unsuitable.
A quantity-limit refusal means the plan will cover less than was prescribed, and the request is for more of something already covered — often the easiest to win.

Ask the plan, in writing if possible, for the specific reason and the specific criterion that was not met. You are entitled to it, and every later step depends on it.

The two things worth doing before appealing anything

Check whether the problem dissolves. Two questions, both quick.

Is there a covered alternative that would work? Not “any drug in the category,” but one your prescriber considers genuinely suitable. If there is, taking it is faster than winning an argument, and nothing prevents you from revisiting the original drug later.

Is the cash price low enough to make coverage irrelevant? For many older generics it is, particularly early in a plan year with an unmet deductible. The tradeoff is that a cash fill generally does not count toward your deductible or out-of-pocket maximum, so this is a better move for a one-off than for an ongoing high-cost medication. Ask the pharmacy for both the insured and the uninsured price before you decide.

If neither applies, appeal.

Level one: the internal appeal

This is a reconsideration by the plan itself, and it usually needs the prescriber’s involvement rather than yours alone. What makes the difference is a letter of medical necessity: a short document from the prescriber saying what the condition is, what has been tried, what happened, why the requested drug is the appropriate choice, and what the consequence of not having it is.

Practical points that change outcomes:

Address the stated criterion directly. If the denial says a preferred drug has not been tried, the letter must say when it was tried and what happened — not that the requested drug is better.
Include dates, even approximate ones. “Tried around 2023, stopped for intolerable side effects” beats a general statement.
Attach the supporting records you have. Prior practices, prior insurers, pharmacy fill histories.
Note the deadline. Plans set a window for filing an appeal, and it is in the denial letter. Missing it forfeits the level.
Ask for expedited review if a delay would be harmful. This is a specific request with a shorter decision window, and it has to be asked for.

Keep a single reference number and a dated log of every call: who you spoke to, what they said, what was promised. This is dull and it is the thing that most reliably shortens the process, because it removes re-explanation from every subsequent contact.

Level two: external review

If the internal appeal fails, most coverage arrangements provide review by an independent body not employed by the plan. The reviewer looks at the same clinical question with fresh eyes, and the plan is generally bound by the outcome.

The mechanics vary by the type of coverage you have — employer plans, individual market plans, and government programmes each have their own route and their own deadlines, all of which are described in the plan documents and in the denial letter itself. Ask the plan to spell out which external review process applies to you and how long you have; that is a reasonable and routine question.

Expedited external review exists too, for the same reason as expedited internal review.

What to do in the meantime

Do not let the paperwork create a gap in a medication you are already taking. This is the practical risk in the whole process, and it is avoidable.

Ask the pharmacy whether a short bridge supply can be dispensed while the request is pending. Sometimes it can.
Ask the prescriber’s office whether samples are available for the interim. For some drugs they are.
Ask whether the manufacturer runs a programme for people in a coverage dispute. Several do, and they are distinct from ordinary copay support — see copay cards and patient assistance programs: how they differ.
Tell the prescriber explicitly if you are close to running out. That fact is what justifies an expedited request, and it cannot be used if it is not stated.

What not to do is stretch a supply by taking less than prescribed without saying so, or buy the medication from a source that ships prescription-only drugs without a prescriber involved. The first is a clinical decision that belongs with your prescriber; the second replaces a coverage problem with a considerably worse one.

Getting help with the process

You do not have to run this alone. Prescriber offices frequently have staff whose job is authorisations and appeals, and asking to speak to that person directly is faster than working through general reception. Many hospital systems have financial counsellors or patient advocates. Disease-specific non-profit organisations often maintain guidance on their condition’s common coverage fights and what arguments succeed. Employer-sponsored plans usually have a benefits contact who can escalate internally.

The framing that helps most

Treat a denial as an incomplete form rather than a verdict. The plan applied written criteria to the information in front of it. Most of the time the disagreement is not about medicine; it is that the plan could not see something you know — a drug tried five years ago, a reaction recorded elsewhere, a reason the obvious alternative will not do. Supplying that missing fact, in the specific terms the criterion asks for, is what wins these.